Molecular therapy for the treatment of hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide. Conventional cytotoxic chemotherapy has failed to show a substantial benefit for patients with HCC. Recently, a number of new drugs targeting molecular mechanisms involved in liver cell transformation have entered into clinica...

Descripción completa

Detalles Bibliográficos
Autores principales: Greten, T F, Korangy, F, Manns, M P, Malek, N P
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Minireview
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2634687/
https://www.ncbi.nlm.nih.gov/pubmed/19018262
http://dx.doi.org/10.1038/sj.bjc.6604784
_version_ 1782164143968616448
author Greten, T F
Korangy, F
Manns, M P
Malek, N P
author_facet Greten, T F
Korangy, F
Manns, M P
Malek, N P
author_sort Greten, T F
collection PubMed
description Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide. Conventional cytotoxic chemotherapy has failed to show a substantial benefit for patients with HCC. Recently, a number of new drugs targeting molecular mechanisms involved in liver cell transformation have entered into clinical trials and led to encouraging results. In this review we summarise this data and point to a number of new compounds, which are currently being tested and can potentially broaden our therapeutic arsenal even further.
format Text
id pubmed-2634687
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-26346872010-01-13 Molecular therapy for the treatment of hepatocellular carcinoma Greten, T F Korangy, F Manns, M P Malek, N P Br J Cancer Minireview Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide. Conventional cytotoxic chemotherapy has failed to show a substantial benefit for patients with HCC. Recently, a number of new drugs targeting molecular mechanisms involved in liver cell transformation have entered into clinical trials and led to encouraging results. In this review we summarise this data and point to a number of new compounds, which are currently being tested and can potentially broaden our therapeutic arsenal even further. Nature Publishing Group 2009-01-13 2008-11-18 /pmc/articles/PMC2634687/ /pubmed/19018262 http://dx.doi.org/10.1038/sj.bjc.6604784 Text en Copyright © 2009 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Minireview
Greten, T F
Korangy, F
Manns, M P
Malek, N P
Molecular therapy for the treatment of hepatocellular carcinoma
title Molecular therapy for the treatment of hepatocellular carcinoma
title_full Molecular therapy for the treatment of hepatocellular carcinoma
title_fullStr Molecular therapy for the treatment of hepatocellular carcinoma
title_full_unstemmed Molecular therapy for the treatment of hepatocellular carcinoma
title_short Molecular therapy for the treatment of hepatocellular carcinoma
title_sort molecular therapy for the treatment of hepatocellular carcinoma
topic Minireview
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2634687/
https://www.ncbi.nlm.nih.gov/pubmed/19018262
http://dx.doi.org/10.1038/sj.bjc.6604784
work_keys_str_mv AT gretentf moleculartherapyforthetreatmentofhepatocellularcarcinoma
AT korangyf moleculartherapyforthetreatmentofhepatocellularcarcinoma
AT mannsmp moleculartherapyforthetreatmentofhepatocellularcarcinoma
AT maleknp moleculartherapyforthetreatmentofhepatocellularcarcinoma

Ejemplares similares